Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) does about 1.17M shares in volume on a normal day but saw 8544406 shares change hands in the recent trading day. The company now has a market cap of 76.91M USD. Its current market price is $2.30, marking a decrease of -11.88% compared to the previous close of $2.61. The 52 week high reached by this stock is $5.67 whilst the lowest price level in 52 weeks is $0.60.
Reviva Pharmaceuticals Holdings Inc (RVPH) has a 20-day trading average at $1.63 and the current price is -59.44% off the 52-week high compared with 283.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.35 and its 200-day simple moving average is $1.75. If we look at the stock’s price movements over the week, volatility stands at 21.58%, which decreases to 21.23% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.87 to suggest the stock is neutral.
The consensus objective for the share price is $15.50, suggesting that the stock has a potential upside of 85.16% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 20, 2023 when ROTH MKM initiated the stock to “Buy” and issued a price target of $12. H.C. Wainwright initiated its price target at $10.
The current price level is 41.02%, 70.30%, and 31.34% away from its SMA20, SMA50, and SMA200 respectively, with the RVPH price moving below the 50-day SMA on current market day. Reviva Pharmaceuticals Holdings Inc (RVPH) stock is up 8.49% over the week and 90.08% over the past month. Its price is -55.34% year-to-date and -39.47% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.23 and -1.0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 85.16 percent from here.
Outstanding shares total 33.44M with insiders holding 14.79% of the shares and institutional holders owning 30.07% of the company’s common stock. The company has a return on equity of -1806.28%. The beta has a value of -0.08.
